FDA advisory panel voted to authorize PFE/BNTX third dose for Americans 65 and older
A U.S. Food and Drug Administration (FDA) advisory panel voted unanimously Friday to authorize Pfizer (PFE)/BioNTech's (BNTX) third dose for Americans 65 and older, and for those with high risk of contracting a severe case of COVID-19.
The vote was the second of the afternoon, after a vote to support full approval for ages 16 and up to receive a booster dose. The new vote also entailed an emergency use authorization, rather than a supplemental approval of the already fully licensed vaccine.
A CDC advisory panel meeting, slated for next week, will delve further into who will qualify for the additional dose.$Pfizer(PFE)$ $BioNTech SE(BNTX)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
